In January 2022, ABBV-399 (also called Teliso-V) was granted the Breakthrough Therapy designation by the FDA for treating advanced or metastatic, platinum-treated, HGFR-overexpressing, EGFR wild-type nonsquamous NSCLC patients. Here, MET is linked to non-small cell lung carcinoma.